Q4 2024 VolitionRX Ltd Earnings Call Transcript
Key Points
- VolitionRX Ltd (VNRX) achieved significant milestones in 2024, including expanding access to the Nu.Q Vet Cancer test across more than 20 countries.
- The company recorded a 59% increase in revenue for 2024, with a notable 75% growth in revenue from the Nu.Q Vet cancer test.
- VolitionRX Ltd (VNRX) has completed several large independent studies supporting the value of their Nu.Q platform, with plans to publish many of these studies in 2025.
- The company is making progress in signing multiple licensing deals for their Nu.Q platform in the human market, with strong interest from large companies.
- VolitionRX Ltd (VNRX) has significantly reduced operating expenses by 23% compared to 2023, contributing to their goal of being cash neutral in 2025.
- Revenues remain unpredictable and lumpy due to the nature of customer purchasing patterns, which can affect quarterly financial performance.
- Despite progress, the company is still in the early stages of commercialization, making revenue forecasts challenging.
- VolitionRX Ltd (VNRX) faces risks and uncertainties related to the successful completion and commercialization of ongoing studies and projects.
- The company is reliant on non-dilutive funding and equity sales to support operations, which may pose financial risks if such funding is not secured.
- The Nu.Q platform's success in the human market is contingent on signing licensing agreements, which are still in progress and not guaranteed.
Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to VolitionRX Limited fourth quarter and full fiscal year 2024 earnings conference call. (Operator Instructions) This conference call is being recorded today, March 31, 2025.
I would now like to turn the conference over to Louise Batchelor, Group Chief Marketing and Communications Officer. Please go ahead.
Thank you, and welcome, everyone, to today's earnings conference call for VolitionRX Limited.
Before we begin, I'd like to remind everyone that some of the information discussed on this conference call will include forward-looking statements covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on our beliefs as well as the assumptions we have used based upon information currently available to us.
Because these statements reflect our current views concerning future events, these statements involve risks
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
